ATE235888T1 - Lyophilisiertes thioxanthenon-antitumormedikament - Google Patents

Lyophilisiertes thioxanthenon-antitumormedikament

Info

Publication number
ATE235888T1
ATE235888T1 AT96929491T AT96929491T ATE235888T1 AT E235888 T1 ATE235888 T1 AT E235888T1 AT 96929491 T AT96929491 T AT 96929491T AT 96929491 T AT96929491 T AT 96929491T AT E235888 T1 ATE235888 T1 AT E235888T1
Authority
AT
Austria
Prior art keywords
lyophilized
antitumor drug
thioxanthenone
thioxanthenone antitumor
mannitol
Prior art date
Application number
AT96929491T
Other languages
English (en)
Inventor
Stephen Brown
Gurdial Singh Sandhu
Original Assignee
Sanofi Synthelabo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo Inc filed Critical Sanofi Synthelabo Inc
Application granted granted Critical
Publication of ATE235888T1 publication Critical patent/ATE235888T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/67Phosphorus compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
AT96929491T 1995-09-18 1996-09-12 Lyophilisiertes thioxanthenon-antitumormedikament ATE235888T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/529,934 US5665760A (en) 1995-09-18 1995-09-18 Lyophilized thioxanthenone antitumor agents
PCT/IB1996/000984 WO1997010809A1 (en) 1995-09-18 1996-09-12 Lyophilized thioxanthenone antimumor agents

Publications (1)

Publication Number Publication Date
ATE235888T1 true ATE235888T1 (de) 2003-04-15

Family

ID=24111801

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96929491T ATE235888T1 (de) 1995-09-18 1996-09-12 Lyophilisiertes thioxanthenon-antitumormedikament

Country Status (20)

Country Link
US (1) US5665760A (de)
EP (1) EP0917458B1 (de)
JP (1) JP2001503374A (de)
KR (1) KR100475385B1 (de)
CN (1) CN1178651C (de)
AT (1) ATE235888T1 (de)
AU (1) AU716782B2 (de)
CA (1) CA2232444A1 (de)
CZ (1) CZ293433B6 (de)
DE (1) DE69627209T2 (de)
DK (1) DK0917458T3 (de)
ES (1) ES2196171T3 (de)
HK (1) HK1016891A1 (de)
HU (1) HUP9900246A3 (de)
NO (1) NO320367B1 (de)
NZ (1) NZ316609A (de)
PL (1) PL185164B1 (de)
PT (1) PT917458E (de)
RU (1) RU2157189C2 (de)
WO (1) WO1997010809A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
GB0115893D0 (en) * 2001-06-28 2001-08-22 Sanofi Synthelabo Formulations
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
BRPI0509117A (pt) * 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
WO2007075452A2 (en) * 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound
WO2010056847A2 (en) * 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582851A (en) * 1984-02-06 1986-04-15 Warner-Lambert Company Anti-bacterial 1,4-aminoalkylamino-9H-thioxanthen-9-one derivatives, compositions, and method of use therefor
US5091410A (en) * 1991-06-10 1992-02-25 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
AU642596B2 (en) * 1991-06-10 1993-10-21 Sanofi-Synthelabo Thioxanthenone antitumor agents

Also Published As

Publication number Publication date
PL185164B1 (pl) 2003-03-31
NO981205D0 (no) 1998-03-17
CZ293433B6 (cs) 2004-04-14
DE69627209T2 (de) 2004-02-19
EP0917458A1 (de) 1999-05-26
DK0917458T3 (da) 2003-07-28
ES2196171T3 (es) 2003-12-16
AU716782B2 (en) 2000-03-09
CA2232444A1 (en) 1997-03-27
RU2157189C2 (ru) 2000-10-10
EP0917458B1 (de) 2003-04-02
AU6888096A (en) 1997-04-09
MX9802143A (es) 1998-05-31
DE69627209D1 (en) 2003-05-08
HUP9900246A2 (hu) 2001-04-28
CN1201387A (zh) 1998-12-09
NO981205L (no) 1998-05-15
PL325603A1 (en) 1998-08-03
CZ79998A3 (cs) 1998-08-12
KR19990045741A (ko) 1999-06-25
PT917458E (pt) 2003-08-29
JP2001503374A (ja) 2001-03-13
WO1997010809A1 (en) 1997-03-27
HK1016891A1 (en) 1999-11-12
US5665760A (en) 1997-09-09
NZ316609A (en) 1999-05-28
NO320367B1 (no) 2005-11-28
KR100475385B1 (ko) 2006-03-23
CN1178651C (zh) 2004-12-08
HUP9900246A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
DE69533551D1 (de) Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
BE2013C033I2 (de)
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
FI960750A (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
PT786257E (pt) Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas
UY25263A1 (es) 6-derivados sustitutivos del ácido micofenólico.-
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
PT971717E (pt) Amino-acucar citotoxico e derivados de acucar afins de indolopirrolocarbazois
ATE355850T1 (de) Lyophilisierte hgf-zubereitungen
ATE235888T1 (de) Lyophilisiertes thioxanthenon-antitumormedikament
IT1270618B (it) Proteine ad attivita' antitumorale
ATE223199T1 (de) Pharmazeutische zusammensetzungen mit laktobazillen zur transmucosalen verabreichung
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
DK0841931T3 (da) Farmaceutisk sammensætning
EP0971725A4 (de) Verfahren zur behandlung von narbengewebe
WO1999031136A3 (en) Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
FR2652266B1 (fr) Vaccin protecteur contre l'hemophilose porcine.
IT1248485B (it) Derivati della 1,4-benzotiazina ad azione immunostimolante e immonomodulatrice

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0917458

Country of ref document: EP

REN Ceased due to non-payment of the annual fee